한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
with the success of "head-to-head" research, kangfang bio broke the dilemma of chinese innovative pharmaceutical companies in the international market, became china's first "billion-dollar" molecule, and quickly established a marca in the global market. their business model has also become the object of learning and imitation for all chinese biotech companies.
the success of kangfang biopharma is not accidental. it has made breakthrough progress in the international market by relying on strict clinical development standards and through "head-to-head" research. this model not only challenges domestic innovative pharmaceutical companies, but also prompts them to find new ways of cooperation to cope with competition in the international market.
mncs, i.e. large pharmaceutical companies, also see the huge potential of akeso and regard it as a "blockbuster" to cope with the performance fluctuations caused by the expiration of product patents. they are eager to seize the business opportunities of akeso and gain an advantageous position in the market competition.
therefore, a unique cooperation model has been formed between mncs and kangfang bio, which is interdependent and jointly promotes the growth of innovative pharmaceutical companies. for example, kangfang’s cooperation with summit is considered a wise move by industry insiders. with its strong capital and experience, summit will help kangfang bio to quickly advance research and development, launch products, and ultimately achieve commercialization.
in addition, the development of china's innovative pharmaceutical companies also depends on the support of external capital. given kangfang bio's current situation, it is necessary to introduce external capital to promote the company's development and expansion.
the rise of akeso biopharma means that china's innovative pharmaceutical companies are entering a new era. their competition in the international market will continue to stimulate their innovation capabilities and promote the development of the entire biopharmaceutical industry.
